Trial Profile
A Clinical Evaluation of AVJ-301 (Absorb BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB Japan
- Sponsors Abbott Vascular
- 26 Mar 2020 Results assessing long-term safety and effectiveness of Absorb BVS compared with XIENCE metallic DES in patients with de novo coronary artery lesions, published in the Circulation Journal.
- 10 Jun 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2018 Results reporting influence of procedural technique on Everolimus-Eluting Stent outcomes within the ABSORB trials (ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics